Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 451-461

  Cazzola, Mario ^a   Calzetta, Luigino ^a   Page, Clive ^b   Jardim, Josè ^c   Chuchalin, Alexander G ^d   Rogliani, Paola ^a   Matera, Maria Gabriella ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; PLACEBO; BRONCHODILATING AGENT;

AGE; ARTHRALGIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPNEA; EDEMA; EPIGASTRIC DISCOMFORT; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL PAIN; GENDER; HEADACHE; HEART PALPITATION; HEARTBURN; HUMAN; INDIGESTION; LOSS OF APPETITE; LOW DRUG DOSE; LUNG FUNCTION TEST; META ANALYSIS (TOPIC); MYALGIA; NAUSEA; PRURITUS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN DISEASE; SMOKING HABIT; SPIROMETRY; SYSTEMATIC REVIEW; TASTE DISORDER; TINNITUS; URTICARIA; VOMITING; WEIGHT GAIN; XEROSTOMIA; BRONCHITIS, CHRONIC; DISEASE COURSE; DRUG EFFECTS; LUNG; META ANALYSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ACETYLCYSTEINE; BRONCHITIS, CHRONIC; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84940663022     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00002215     Document Type: Review

References (38)

1. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2: 187-194.
2. Cazzola M, Matera MG. N-acetylcysteine in COPD may be beneficial, but for whom? Lancet Respir Med 2014; 2: 166-167.
3. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-1560.
4. Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22: 209-221.
5. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-262.
6. Shen Y, Cai W, Lei S, et al. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD 2014; 11: 351-358.
7. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
8. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
9. World Health Organization. International Classification of Diseases. Manual of the International Statistical Classification of Diseases: Injuries and Causes of Deaths. 9th revision. Geneva, World Health Organization, 1977.
10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html Date last accessed: March, 2015. Date last updated: January, 2015.
11. Shariff SZ, Bejaimal SA, Sontrop JM, et al. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches. J Med Internet Res 2013; 15: e164.
12. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD 2006; 3: 195-202.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Borenstein M. Introduction to Meta-analysis. Chichester, John Wiley & Sons, 2009.
15. DeCoster J. Meta-analysis Notes. www.stat-help.com/notes.html Date last accessed: March, 2015. Date last updated: September, 2004.
16. Turner JR, Durham TA. Meta-methodology: conducting and reporting meta-analyses. J Clin Hypertens (Greenwich) 2014; 16: 91-93.
17. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012; 49: 1-15.
18. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2012; 36: 1-48.
19. Hansen NC, Skriver A, Brorsen-Riis L, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531-535.
20. Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144: 106-118.
21. Babolini G, Blasi A, Comia G, et al. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis Suppl 1980; 111: 93-108.
22. McGavin CR, MacFarlane JT, Prescott RJ, et al. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax 1985; 40: 832-835.
23. Boman G, Bäcker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64: 405-415.
24. Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999; 66: 495-500.
25. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-355.
26. Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009; 103: 542-551.
27. Bachh AA, Shah NN, Bhargava R, et al. Effect of oral N-acetylcysteine in COPD -a randomised controlled trial. JK Practitioner 2007; 14: 12-16.
28. Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 1976; 9: 393-396.
29. Gerrits CM, Herings RM, Leufkens HG, et al. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 795-798.
30. Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009; 64: 894-900.
31. Jamal K, Cooney TP, Fleetham JA, et al. Chronic bronchitis. Correlation of morphologic findings to sputum production and flow rates. Am Rev Respir Dis 1984; 129: 719-722.
32. Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993-1013.
33. Segreti A, Stirpe E, Rogliani P, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther 2014; 18: 381-388.
34. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 2012; 48: 86-98.
35. Tse HN, Raiteri L, Wong KY, et al. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. Chest 2014; 146: 611-623.
36. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society guideline. Chest 2015; 147: 883-893.
37. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 2014; 141: 150-159.
38. Sadowska AM, Manuel-y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 2007; 20: 9-22.